

Ian Reid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/488820/publications.pdf>

Version: 2024-02-01

423
papers

38,762
citations

2213

99
h-index

3181

186
g-index

445
all docs

445
docs citations

445
times ranked

23701
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2009, 361, 756-765. | 13.9 | 2,747 |
| 2 | Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 356, 1809-1822. | 13.9 | 2,536 |
| 3 | Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. <i>Nature Genetics</i> , 2012, 44, 491-501. | 9.4 | 1,100 |
| 4 | Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 3-23. | 3.1 | 957 |
| 5 | Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c3691-c3691. | 2.4 | 931 |
| 6 | Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2002, 346, 653-661. | 13.9 | 827 |
| 7 | Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040. | 2.4 | 740 |
| 8 | Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266. | 2.4 | 585 |
| 9 | The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 243-254. | 3.1 | 552 |
| 10 | Relationships among body mass, its components, and bone11Published simultaneously at BoneKEy-Osteovision (http://www.bonekey-ibms.org), a Web site sponsored by the International Bone and Mineral Society.. <i>Bone</i> , 2002, 31, 547-555. | 1.4 | 551 |
| 11 | Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. <i>Lancet, The</i> , 2014, 383, 146-155. | 6.3 | 497 |
| 12 | Effect of Calcium Supplementation on Bone Loss in Postmenopausal Women. <i>New England Journal of Medicine</i> , 1993, 328, 460-464. | 13.9 | 495 |
| 13 | Postmenopausal osteoporosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16069. | 18.1 | 462 |
| 14 | Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. <i>American Journal of Medicine</i> , 1995, 98, 331-335. | 0.6 | 410 |
| 15 | Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. <i>Journal of Endocrinology</i> , 2002, 175, 405-415. | 1.2 | 404 |
| 16 | The Peroxisome Proliferator-Activated Receptor- β Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1305-1310. | 1.8 | 399 |
| 17 | Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease. <i>New England Journal of Medicine</i> , 2005, 353, 898-908. | 13.9 | 397 |
| 18 | Relationships between fat and bone. <i>Osteoporosis International</i> , 2008, 19, 595-606. | 1.3 | 394 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 307-320. | 5.5 | 371 |
| 20 | Determinants of total body and regional bone mineral density in normal postmenopausal women—a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 45-51. | 1.8 | 367 |
| 21 | Determinants of total body and regional bone mineral density in normal postmenopausal women—a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 45-51. | 1.8 | 348 |
| 22 | Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. <i>Bone</i> , 2007, 41, 318-320. | 1.4 | 332 |
| 23 | Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 779-782. | 1.8 | 311 |
| 24 | PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD). <i>Lancet</i> , 1988, 331, 143-146. | 6.3 | 305 |
| 25 | Fat and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 20-27. | 1.4 | 303 |
| 26 | Testosterone Therapy in Glucocorticoid-Treated Men. <i>Archives of Internal Medicine</i> , 1996, 156, 1173. | 4.3 | 290 |
| 27 | Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1174-1181. | 1.8 | 285 |
| 28 | Fracture Prevention with Zoledronate in Older Women with Osteopenia. <i>New England Journal of Medicine</i> , 2018, 379, 2407-2416. | 13.9 | 280 |
| 29 | Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 779-782. | 1.8 | 276 |
| 30 | Calcium intake and bone mineral density: systematic review and meta-analysis. <i>BMJ</i> , 2015, 351, h4183. | 3.0 | 272 |
| 31 | Randomized Controlled Trial of Calcium in Healthy Older Women. <i>American Journal of Medicine</i> , 2006, 119, 777-785. | 0.6 | 249 |
| 32 | Osteonecrosis of the jaw “Who gets it, and why?”. <i>Bone</i> , 2009, 44, 4-10. | 1.4 | 243 |
| 33 | Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149. | 2.2 | 243 |
| 34 | Calcium intake and risk of fracture: systematic review. <i>BMJ</i> , 2015, 351, h4580. | 3.0 | 241 |
| 35 | WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. <i>PLoS Genetics</i> , 2012, 8, e1002745. | 1.5 | 240 |
| 36 | Glucocorticoid osteoporosis—mechanisms and management. <i>European Journal of Endocrinology</i> , 1997, 137, 209-217. | 1.9 | 238 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. PLoS Genetics, 2011, 7, e1001372. | 1.5 | 233 |
| 38 | Bone density in women receiving depot medroxyprogesterone acetate for contraception.. BMJ: British Medical Journal, 1991, 303, 13-16. | 2.4 | 229 |
| 39 | Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial. Lancet, The, 2001, 357, 509-512. | 6.3 | 227 |
| 40 | Pathogenesis and management of Paget's disease of bone. Lancet, The, 2008, 372, 155-163. | 6.3 | 227 |
| 41 | Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. Journal of Bone and Mineral Research, 2011, 26, 242-251. | 3.1 | 220 |
| 42 | Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. Journal of Bone and Mineral Research, 2010, 25, 2256-2265. | 3.1 | 218 |
| 43 | Effects of calcium supplementation on serum lipid concentrations in normal older women.. American Journal of Medicine, 2002, 112, 343-347. | 0.6 | 213 |
| 44 | The Influence of Osteophytes and Aortic Calcification on Spinal Mineral Density in Postmenopausal Women*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 1372-1374. | 1.8 | 208 |
| 45 | Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4380-4387. | 1.8 | 206 |
| 46 | The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2015, 30, 934-944. | 3.1 | 205 |
| 47 | Drug therapy for osteoporosis in older adults. Lancet, The, 2022, 399, 1080-1092. | 6.3 | 193 |
| 48 | In Vitro and in Vivo Effects of Adiponectin on Bone. Endocrinology, 2009, 150, 3603-3610. | 1.4 | 190 |
| 49 | Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research, 2008, 23, 6-16. | 3.1 | 189 |
| 50 | Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2011, 26, 530-537. | 3.1 | 188 |
| 51 | Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Journal of Clinical Densitometry, 2017, 20, 8-24. | 0.5 | 185 |
| 52 | Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1525-1530. | 1.8 | 183 |
| 53 | PATHOGENESIS AND TREATMENT OF STEROID OSTEOPOROSIS. Clinical Endocrinology, 1989, 30, 83-103. | 1.2 | 178 |
| 54 | Effects of Vitamin D Supplementation on Strength, Physical Performance, and Falls in Older Persons: A Systematic Review. Journal of the American Geriatrics Society, 2003, 51, 1219-1226. | 1.3 | 176 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 959-964. | 2.2 | 173 |
| 56 | Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. <i>American Journal of Medicine</i> , 2000, 109, 362-370. | 0.6 | 170 |
| 57 | Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. <i>American Journal of Medicine</i> , 1996, 101, 341-348. | 0.6 | 164 |
| 58 | Effect of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Mild Primary Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1996, 125, 360. | 2.0 | 159 |
| 59 | Evaluation of the FRAX and Garvan fracture risk calculators in older women. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 420-427. | 3.1 | 158 |
| 60 | Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 687-693. | 3.1 | 156 |
| 61 | High-dose oral vitamin D3 supplementation in the elderly. <i>Osteoporosis International</i> , 2009, 20, 1407-1415. | 1.3 | 153 |
| 62 | Bisphosphonates in pregnancy and lactation-associated osteoporosis. <i>Osteoporosis International</i> , 2006, 17, 1008-1012. | 1.3 | 151 |
| 63 | Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. <i>Bone</i> , 2001, 29, 162-168. | 1.4 | 149 |
| 64 | Vitamin D supplementation and falls: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 573-580. | 5.5 | 149 |
| 65 | Short-term and long-term effects of osteoporosis therapies. <i>Nature Reviews Endocrinology</i> , 2015, 11, 418-428. | 4.3 | 147 |
| 66 | The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. <i>American Journal of Medicine</i> , 1995, 99, 636-641. | 0.6 | 144 |
| 67 | Epidemiology and pathogenesis of osteonecrosis of the jaw. <i>Nature Reviews Rheumatology</i> , 2012, 8, 90-96. | 3.5 | 144 |
| 68 | Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4408-4422. | 1.8 | 138 |
| 69 | β -Blocker Use, BMD, and Fractures in the Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 613-618. | 3.1 | 136 |
| 70 | Normal bone mineral density following cure of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1992, 36, 229-234. | 1.2 | 134 |
| 71 | Insulin increases histomorphometric indices of bone formation In vivo. <i>Calcified Tissue International</i> , 1996, 59, 492-495. | 1.5 | 134 |
| 72 | Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 142-148. | 3.1 | 132 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Enhanced osteoclastogenesis in patients with tophaceous gout: Urate crystals promote osteoclast development through interactions with stromal cells. <i>Arthritis and Rheumatism</i> , 2008, 58, 1854-1865. | 6.7 | 132 |
| 74 | A broader strategy for osteoporosis interventions. <i>Nature Reviews Endocrinology</i> , 2020, 16, 333-339. | 4.3 | 132 |
| 75 | Activation of Peroxisome Proliferator-Activated Receptor $\hat{1}^3$ (PPAR $\hat{1}^3$) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in Vivo. <i>Endocrinology</i> , 2007, 148, 903-911. | 1.4 | 130 |
| 76 | Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. <i>Human Molecular Genetics</i> , 2014, 23, 1923-1933. | 1.4 | 130 |
| 77 | Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10. | 3.1 | 127 |
| 78 | Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. <i>Bone</i> , 2006, 38, 317-321. | 1.4 | 126 |
| 79 | Determinants of the rate of bone loss in normal postmenopausal women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 950-954. | 1.8 | 124 |
| 80 | Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. <i>Archives of Internal Medicine</i> , 2008, 168, 2276. | 4.3 | 122 |
| 81 | Determinants of vitamin D status in older women living in a subtropical climate. <i>Osteoporosis International</i> , 2005, 16, 1641-1648. | 1.3 | 121 |
| 82 | Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1283-1288. | 1.8 | 119 |
| 83 | Vitamin D insufficiency and health outcomes over 5 y in older women. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 82-89. | 2.2 | 119 |
| 84 | Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4522-4528. | 1.8 | 118 |
| 85 | Amylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice. <i>Biochemical and Biophysical Research Communications</i> , 1995, 207, 133-139. | 1.0 | 116 |
| 86 | The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. <i>Osteoporosis International</i> , 2007, 18, 479-486. | 1.3 | 115 |
| 87 | Modulation of Osteoclastogenesis by Fatty Acids. <i>Endocrinology</i> , 2008, 149, 5688-5695. | 1.4 | 115 |
| 88 | A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2261-2270. | 3.1 | 115 |
| 89 | Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1595-1599. | 1.8 | 114 |
| 90 | Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. <i>Journal of the American Dental Association</i> , 2008, 139, 32-40. | 0.7 | 114 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Effect of calcium supplementation on hip fractures. <i>Osteoporosis International</i> , 2008, 19, 1119-1123. | 1.3 | 111 |
| 92 | Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 899-911. | 5.5 | 111 |
| 93 | Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1627-1634. | 3.1 | 109 |
| 94 | Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1348-1354. | 3.1 | 109 |
| 95 | Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4546-4554. | 1.8 | 109 |
| 96 | Effects of Leptin on the Skeleton. <i>Endocrine Reviews</i> , 2018, 39, 938-959. | 8.9 | 107 |
| 97 | Effects of Calcium Supplementation on Body Weight and Blood Pressure in Normal Older Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3824-3829. | 1.8 | 106 |
| 98 | Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. <i>Osteoporosis International</i> , 1994, 4, 362-367. | 1.3 | 105 |
| 99 | Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo*. <i>Endocrinology</i> , 1997, 138, 1299-1304. | 1.4 | 104 |
| 100 | Determinants of the rate of bone loss in normal postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 950-954. | 1.8 | 104 |
| 101 | Circulating insulin levels are related to bone density in normal postmenopausal women. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993, 265, E655-E659. | 1.8 | 103 |
| 102 | Calcium supplements: benefits and risks. <i>Journal of Internal Medicine</i> , 2015, 278, 354-368. | 2.7 | 101 |
| 103 | The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 538-544. | 1.8 | 100 |
| 104 | Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2017, 282, 452-460. | 2.7 | 100 |
| 105 | THE ACUTE BIOCHEMICAL EFFECTS OF FOUR PROPRIETARY CALCIUM PREPARATIONS. <i>Australian and New Zealand Journal of Medicine</i> , 1986, 16, 193-197. | 0.5 | 99 |
| 106 | Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. <i>Bone</i> , 2004, 35, 224-230. | 1.4 | 99 |
| 107 | Skeletal phenotype of the leptin receptor-deficient mouse. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1698-1709. | 3.1 | 98 |
| 108 | Effects of a β -Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5212-5216. | 1.8 | 97 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 1221-1225. | 3.1 | 97 |
| 110 | Circulating calcium concentrations, vascular disease and mortality: a systematic review. <i>Journal of Internal Medicine</i> , 2016, 279, 524-540. | 2.7 | 97 |
| 111 | Evidence for Decreased Tubular Reabsorption of Calcium in Glucocorticoid-Treated Asthmatics. <i>Hormone Research</i> , 1987, 27, 200-204. | 1.8 | 95 |
| 112 | Bone Loss After Denosumab: Only Partial Protection with Zoledronate. <i>Calcified Tissue International</i> , 2017, 101, 371-374. | 1.5 | 95 |
| 113 | Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 963-974. | 3.1 | 94 |
| 114 | Cardiovascular effects of calcium supplementation. <i>Osteoporosis International</i> , 2011, 22, 1649-1658. | 1.3 | 93 |
| 115 | Body Weight and Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1994, 121, 745. | 2.0 | 92 |
| 116 | 25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1464-1469. | 3.1 | 92 |
| 117 | Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 131-139. | 2.2 | 91 |
| 118 | Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1677-1682. | 0.5 | 90 |
| 119 | Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. <i>Human Molecular Genetics</i> , 2014, 23, 3054-3068. | 1.4 | 90 |
| 120 | The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. <i>Clinical Endocrinology</i> , 1998, 49, 615-618. | 1.2 | 88 |
| 121 | Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. <i>Osteoporosis International</i> , 1992, 2, 103-105. | 1.3 | 85 |
| 122 | Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 1994, 40, 671-677. | 1.2 | 85 |
| 123 | Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1653-1662. | 1.8 | 85 |
| 124 | Relationships between vascular calcification, calcium metabolism, bone density, and fractures. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2777-2785. | 3.1 | 83 |
| 125 | Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 929-934. | 0.5 | 83 |
| 126 | Five years of anti-resorptive activity after a single dose of zoledronate—Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393. | 1.4 | 83 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age specific rates of hip fracture. <i>BMJ: British Medical Journal</i> , 1994, 309, 508-509. | 2.4 | 82 |
| 128 | Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2013, 110, 1384-1393. | 1.2 | 81 |
| 129 | Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism. <i>Archives of Internal Medicine</i> , 2000, 160, 2161. | 4.3 | 78 |
| 130 | Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. <i>Clinical Endocrinology</i> , 2002, 56, 703-711. | 1.2 | 78 |
| 131 | Effects of Calcium Supplementation on Circulating Lipids. <i>Drugs and Aging</i> , 2004, 21, 7-17. | 1.3 | 78 |
| 132 | Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 557-563. | 1.8 | 78 |
| 133 | Regular exercise dissociates fat mass and bone density in premenopausal women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1764-1768. | 1.8 | 77 |
| 134 | Stimulation of Osteoblast Proliferation by C-Terminal Fragments of Parathyroid Hormone-Related Protein. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 915-922. | 3.1 | 76 |
| 135 | Differential Gene Expression in Cultured Osteoblasts and Bone Marrow Stromal Cells From Patients With Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 298-309. | 3.1 | 76 |
| 136 | Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. <i>Calcified Tissue International</i> , 2018, 103, 55-61. | 1.5 | 76 |
| 137 | Efficacy, effectiveness and side effects of medications used to prevent fractures. <i>Journal of Internal Medicine</i> , 2015, 277, 690-706. | 2.7 | 75 |
| 138 | Calcium and Cardiovascular Disease. <i>Endocrinology and Metabolism</i> , 2017, 32, 339. | 1.3 | 75 |
| 139 | Postâ€pregnancy osteoporosis associated with hypercalcaemia. <i>Clinical Endocrinology</i> , 1992, 37, 298-303. | 1.2 | 74 |
| 140 | Preptin, another peptide product of the pancreatic Î²-cell, is osteogenic in vitro and in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E117-E122. | 1.8 | 74 |
| 141 | Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 505-512. | 3.1 | 74 |
| 142 | Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. <i>Clinical Endocrinology</i> , 2007, 67, 259-264. | 1.2 | 73 |
| 143 | Does calcium supplementation increase cardiovascular risk?. <i>Clinical Endocrinology</i> , 2010, 73, 689-695. | 1.2 | 73 |
| 144 | Determinants of vitamin D status in older men living in a subtropical climate. <i>Osteoporosis International</i> , 2006, 17, 1742-1748. | 1.3 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Anti-resorptive therapies for osteoporosis. <i>Seminars in Cell and Developmental Biology</i> , 2008, 19, 473-478. | 2.3 | 69 |
| 146 | A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women. <i>Archives of Internal Medicine</i> , 2004, 164, 871. | 4.3 | 68 |
| 147 | Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2721-2731. | 1.8 | 68 |
| 148 | Nutrition-Related Peptides and Bone Homeostasis. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 495-500. | 3.1 | 67 |
| 149 | Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 20-27. | 3.1 | 63 |
| 150 | Regular exercise dissociates fat mass and bone density in premenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1764-1768. | 1.8 | 63 |
| 151 | Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E694-E699. | 1.8 | 60 |
| 152 | Failure to Detect Measles Virus Ribonucleic Acid in Bone Cells from Patients with Paget's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1398-1401. | 1.8 | 60 |
| 153 | Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2006, 355, 2494-2495. | 13.9 | 59 |
| 154 | Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. <i>Bone</i> , 2011, 49, 710-716. | 1.4 | 59 |
| 155 | TWO-YEAR FOLLOW-UP OF BIPHOSPHONATE (APD) TREATMENT IN STEROID OSTEOPOROSIS. <i>Lancet</i> , The, 1988, 332, 1144. | 6.3 | 57 |
| 156 | Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases*. <i>Endocrinology</i> , 2001, 142, 1098-1106. | 1.4 | 57 |
| 157 | Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2251-2255. | 3.1 | 57 |
| 158 | Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2051-2056. | 3.1 | 56 |
| 159 | Calcium supplements and cardiovascular risk: 5 years on. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 199-210. | 1.0 | 55 |
| 160 | Vitamin D Effect on Bone Mineral Density and Fractures. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 935-945. | 1.2 | 55 |
| 161 | Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 433-438. | 3.1 | 54 |
| 162 | The Incidence of Acute Anterior Uveitis after Intravenous Zoledronate. <i>Ophthalmology</i> , 2013, 120, 773-776. | 2.5 | 54 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Prevention of glucocorticoid-induced osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 619-623. | 3.1 | 53 |
| 164 | Decreased bone density in men on methadone maintenance therapy. <i>Addiction</i> , 2011, 106, 349-354. | 1.7 | 53 |
| 165 | Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4265-4272. | 1.8 | 53 |
| 166 | Glucocorticoid Osteoporosis. <i>Journal of Asthma</i> , 1994, 31, 7-18. | 0.9 | 52 |
| 167 | Bisphosphonates: new indications and methods of administration. <i>Current Opinion in Rheumatology</i> , 2003, 15, 458-463. | 2.0 | 52 |
| 168 | Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928. | 1.8 | 50 |
| 169 | Bone mineral density remains stable in HAART-treated HIV-infected men over 2Âyears. <i>Clinical Endocrinology</i> , 2007, 67, 270-275. | 1.2 | 49 |
| 170 | Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 1996, 44, 696-702. | 1.2 | 48 |
| 171 | Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. <i>Medical Journal of Australia</i> , 2009, 190, 316-320. | 0.8 | 48 |
| 172 | Steroid osteoporosis. <i>Calcified Tissue International</i> , 1989, 45, 63-67. | 1.5 | 47 |
| 173 | Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 240-246. | 1.0 | 47 |
| 174 | Treatment of Pagetâ€™s Disease of Bone with Denosumab: Case Report and Literature Review. <i>Calcified Tissue International</i> , 2016, 99, 322-325. | 1.5 | 46 |
| 175 | Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. <i>Clinical Endocrinology</i> , 2006, 65, 191-197. | 1.2 | 45 |
| 176 | Evidence for anti-osteoporosis therapy in acute fracture situationsâ€”Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. <i>Bone</i> , 2010, 46, 267-271. | 1.4 | 45 |
| 177 | Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. <i>Clinical Endocrinology</i> , 1996, 44, 293-296. | 1.2 | 44 |
| 178 | Osteonecrosis of the jaw. <i>Skeletal Radiology</i> , 2009, 38, 5-9. | 1.2 | 44 |
| 179 | Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. <i>Climacteric</i> , 2015, 18, 22-31. | 1.1 | 44 |
| 180 | The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. <i>New Zealand Medical Journal</i> , 2008, 121, 63-74. | 0.5 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292. | 1.8 | 43 |
| 182 | Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. <i>Osteoporosis International</i> , 2014, 25, 2347-2357. | 1.3 | 43 |
| 183 | Controversies in medicine: the role of calcium and vitamin D supplements in adults. <i>Medical Journal of Australia</i> , 2019, 211, 468-473. | 0.8 | 43 |
| 184 | Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020, 12, 1011. | 1.7 | 43 |
| 185 | Insulin Increases Histomorphometric Indices of Bone Formation In Vivo. <i>Calcified Tissue International</i> , 1996, 59, 492-495. | 1.5 | 43 |
| 186 | Testosterone therapy in glucocorticoid-treated men. <i>Archives of Internal Medicine</i> , 1996, 156, 1173-7. | 4.3 | 43 |
| 187 | Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women. <i>British Journal of Nutrition</i> , 2014, 112, 1611-1620. | 1.2 | 42 |
| 188 | Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1304-1308. | 3.1 | 41 |
| 189 | Determinants of sex hormone-binding globulin in normal postmenopausal women. <i>Clinical Endocrinology</i> , 2001, 54, 81-87. | 1.2 | 40 |
| 190 | Zoledronate. <i>Bone</i> , 2020, 137, 115390. | 1.4 | 39 |
| 191 | Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012, 45, 43-48. | 0.8 | 38 |
| 192 | Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012, 98, 609-614. | 1.2 | 38 |
| 193 | Bisphosphonates in Paget's disease. <i>Bone</i> , 2011, 49, 89-94. | 1.4 | 37 |
| 194 | Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1091-1094. | 0.5 | 37 |
| 195 | The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014, 170, 255-262. | 1.9 | 37 |
| 196 | Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 499-503. | 1.3 | 37 |
| 197 | Calcium supplements: bad for the heart?. <i>Heart</i> , 2012, 98, 895-896. | 1.2 | 36 |
| 198 | Skeletal health in adults with HIV infection. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 63-74. | 5.5 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Cardiovascular Effects of Calcium Supplements. <i>Nutrients</i> , 2013, 5, 2522-2529. | 1.7 | 35 |
| 200 | Should We Prescribe Calcium Supplements For Osteoporosis Prevention?. <i>Journal of Bone Metabolism</i> , 2014, 21, 21. | 0.5 | 35 |
| 201 | Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021, 24, 3-13. | 0.5 | 35 |
| 202 | Calcium supplementation: Balancing the cardiovascular risks. <i>Maturitas</i> , 2011, 69, 289-295. | 1.0 | 34 |
| 203 | What diseases are causally linked to vitamin D deficiency?. <i>Archives of Disease in Childhood</i> , 2016, 101, 185-189. | 1.0 | 34 |
| 204 | Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. <i>Cmaj</i> , 2017, 189, E1130-E1136. | 0.9 | 34 |
| 205 | Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. <i>Skeletal Radiology</i> , 2011, 40, 1191-1196. | 1.2 | 33 |
| 206 | Randomised controlled trial of vitamin D supplementation in sarcoidosis. <i>BMJ Open</i> , 2013, 3, e003562. | 0.8 | 33 |
| 207 | Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 753-756. | 3.1 | 33 |
| 208 | Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. <i>Osteoporosis International</i> , 2016, 27, 2099-2107. | 1.3 | 32 |
| 209 | Absence of Somatic SQSTM1 Mutations in Paget's Disease of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 691-694. | 1.8 | 31 |
| 210 | Calcium risk-benefit updated—New WHI analyses. <i>Maturitas</i> , 2014, 77, 1-3. | 1.0 | 31 |
| 211 | Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women. <i>British Journal of Nutrition</i> , 2015, 114, 1868-1874. | 1.2 | 31 |
| 212 | Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. <i>Archives of Internal Medicine</i> , 1990, 150, 2545-8. | 4.3 | 31 |
| 213 | Calcitropic Hormone Levels in Polynesians: Evidence against Their Role in Interracial Differences in Bone Mass*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1452-1456. | 1.8 | 30 |
| 214 | Cardiovascular Complications of Calcium Supplements. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 494-501. | 1.2 | 30 |
| 215 | Premature Hair Graying and Bone Mineral Density ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3580-3583. | 1.8 | 29 |
| 216 | Osteoporosis treatment: Focus on safety. <i>European Journal of Internal Medicine</i> , 2013, 24, 691-697. | 1.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Vitamin D: The More We Know, the Less We Know. <i>Clinical Chemistry</i> , 2015, 61, 462-465. | 1.5 | 29 |
| 218 | Ototoxicity associated with intravenous bisphosphonate administration. <i>Calcified Tissue International</i> , 1995, 56, 584-585. | 1.5 | 28 |
| 219 | Steroid-induced osteoporosis. <i>Osteoporosis International</i> , 1997, 7, 213-216. | 1.3 | 28 |
| 220 | Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 93-107. | 1.0 | 28 |
| 221 | Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647. | 1.8 | 28 |
| 222 | Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. <i>Osteoporosis International</i> , 2021, 32, 1249-1275. | 1.3 | 28 |
| 223 | Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo. <i>Endocrinology</i> , 1997, 138, 1299-1304. | 1.4 | 28 |
| 224 | Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1437-1445. | 3.1 | 28 |
| 225 | Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 984-992. | 3.1 | 27 |
| 226 | The effect of leukemia inhibitory factor on bone in vivo. <i>Endocrinology</i> , 1993, 132, 1359-1366. | 1.4 | 27 |
| 227 | Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. <i>Clinical Endocrinology</i> , 1997, 46, 87-92. | 1.2 | 26 |
| 228 | The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2008, 48, 195-197. | 0.9 | 26 |
| 229 | Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro. <i>International Journal of Peptides</i> , 2011, 2011, 1-7. | 0.7 | 26 |
| 230 | Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial. <i>British Journal of Nutrition</i> , 2015, 113, 1585-1594. | 1.2 | 26 |
| 231 | Obesity and osteoporosis. <i>Annales D'Endocrinologie</i> , 2006, 67, 125-129. | 0.6 | 25 |
| 232 | The Auckland calcium study: 5-year post-trial follow-up. <i>Osteoporosis International</i> , 2014, 25, 297-304. | 1.3 | 25 |
| 233 | Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1044-1051. | 0.5 | 25 |
| 234 | Alteration of bone cell function by RANKL and OPG in different in vitro models. <i>European Journal of Clinical Investigation</i> , 2007, 37, 407-415. | 1.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Actions of fibroblast growth factor-8 in bone cells in vitro. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E142-E150. | 1.8 | 24 |
| 236 | Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clinical Endocrinology, 2012, 76, 643-648. | 1.2 | 24 |
| 237 | Direct Actions of Leptin on Bone Remodeling. Calcified Tissue International, 2004, 74, 313-316. | 1.5 | 23 |
| 238 | Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3576-3584. | 1.8 | 23 |
| 239 | Relationships between upper-arm anthropometry and soft-tissue composition in postmenopausal women. American Journal of Clinical Nutrition, 1992, 56, 463-466. | 2.2 | 22 |
| 240 | Hormone Replacement Therapy Causes a Respiratory Alkalosis in Normal Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1997-2001. | 1.8 | 22 |
| 241 | Calcium supplementation and vascular disease. Climacteric, 2008, 11, 280-286. | 1.1 | 22 |
| 242 | Effects of beta-blockers on fracture risk. Journal of Musculoskeletal Neuronal Interactions, 2008, 8, 105-10. | 0.1 | 22 |
| 243 | Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2446-2452. | 1.8 | 21 |
| 244 | Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2014, 29, 166-172. | 3.1 | 21 |
| 245 | Effects of vitamin D supplements on bone density. Journal of Endocrinological Investigation, 2015, 38, 91-94. | 1.8 | 21 |
| 246 | Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study. Journal of Bone and Mineral Research, 2015, 30, 570-574. | 3.1 | 21 |
| 247 | Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. Journal of Internal Medicine, 2019, 286, 221-229. | 2.7 | 21 |
| 248 | Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Therapeutics and Clinical Risk Management, 2006, 2, 77-86. | 0.9 | 21 |
| 249 | Evidence-based policy on dietary calcium and vitamin D. Journal of Bone and Mineral Research, 2011, 26, 452-454. | 3.1 | 20 |
| 250 | The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporosis International, 2013, 24, 349-354. | 1.3 | 20 |
| 251 | Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2301-2307. | 1.8 | 20 |
| 252 | Benefits of Bisphosphonate Therapy: Beyond the Skeleton. Current Osteoporosis Reports, 2020, 18, 587-596. | 1.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | INSULIN-LIKE GROWTH FACTOR 1 AND BONE TURNOVER IN GLUCOCORTICOID-TREATED AND CONTROL SUBJECTS. <i>Clinical Endocrinology</i> , 1989, 30, 347-353. | 1.2 | 19 |
| 254 | Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—Secondary analysis of a randomized controlled trial. <i>Bone</i> , 2005, 37, 190-191. | 1.4 | 19 |
| 255 | Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008, 189, 674-675. | 0.8 | 19 |
| 256 | Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. <i>Calcified Tissue International</i> , 2019, 105, 107-108. | 1.5 | 19 |
| 257 | Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. <i>New Zealand Medical Journal</i> , 2003, 116, U536. | 0.5 | 19 |
| 258 | Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases. <i>Endocrinology</i> , 2001, 142, 1098-1106. | 1.4 | 18 |
| 259 | Bisphosphonates. <i>Skeletal Radiology</i> , 2007, 36, 711-714. | 1.2 | 16 |
| 260 | Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women. <i>Osteoporosis International</i> , 2010, 21, 1935-1941. | 1.3 | 16 |
| 261 | Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. <i>BoneKey Reports</i> , 2013, 2, 442. | 2.7 | 16 |
| 262 | Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. <i>BMJ Open</i> , 2013, 3, e002334. | 0.8 | 16 |
| 263 | What factors modify the effect of monthly bolus dose vitamin D supplementation on 25-hydroxyvitamin D concentrations?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 201, 105687. | 1.2 | 16 |
| 264 | Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 805-807. | 0.2 | 15 |
| 265 | Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1487-1493. | 3.1 | 15 |
| 266 | Testosterone Levels Following Decreases in Serum Osteocalcin. <i>Calcified Tissue International</i> , 2013, 93, 133-136. | 1.5 | 15 |
| 267 | Subgroup analysis for the risk of cardiovascular disease with calcium supplements. <i>BoneKey Reports</i> , 2013, 2, 293. | 2.7 | 15 |
| 268 | Metabolic bone disease. , 2014, , 604-635. | | 15 |
| 269 | Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab. <i>BioDrugs</i> , 2017, 31, 289-297. | 2.2 | 15 |
| 270 | Time for a moratorium on vitamin D meta-analyses?. <i>BMJ: British Medical Journal</i> , 2009, 339, b4394-b4394. | 2.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | A Potential Role for Adrenomedullin as a Local Regulator of Bone Growth. <i>Endocrinology</i> , 2001, 142, 1849-1857. | 1.4 | 15 |
| 272 | Artifact in the control group undermines the conclusions of a vitamin D and cancer study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-792. | 2.2 | 14 |
| 273 | The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate. <i>Calcified Tissue International</i> , 2015, 97, 58-61. | 1.5 | 14 |
| 274 | Calcium Supplements Increase Risk of Myocardial Infarction. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 389-390. | 3.1 | 14 |
| 275 | Dietary calcium intake and rate of bone loss in men. <i>British Journal of Nutrition</i> , 2017, 117, 1432-1438. | 1.2 | 14 |
| 276 | Serum phosphate is related to adiposity in healthy adults. <i>European Journal of Clinical Investigation</i> , 2017, 47, 486-493. | 1.7 | 14 |
| 277 | Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 196-205. | 1.3 | 14 |
| 278 | Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11. | 3.1 | 14 |
| 279 | Pharmacotherapy of Paget's disease of bone. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 637-646. | 0.9 | 13 |
| 280 | Bone density is normal and does not change over 2 years in sarcoidosis. <i>Osteoporosis International</i> , 2015, 26, 611-616. | 1.3 | 13 |
| 281 | Pharmacological Management of Osteoporosis in Postmenopausal Women. <i>Drugs and Aging</i> , 1999, 15, 349-363. | 1.3 | 12 |
| 282 | Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-793. | 2.2 | 12 |
| 283 | Reprint: Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012, 45, 970-975. | 0.8 | 12 |
| 284 | Path Analysis Identifies Receptor Activator of Nuclear Factor- κ B Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout. <i>Journal of Rheumatology</i> , 2016, 43, 445-449. | 1.0 | 12 |
| 285 | Management of Paget's disease of bone. <i>Osteoporosis International</i> , 2020, 31, 827-837. | 1.3 | 12 |
| 286 | The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 21-28. | 3.1 | 12 |
| 287 | Towards a trial-based definition of vitamin D deficiency. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 376-377. | 5.5 | 11 |
| 288 | Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2016, 27, 1209-1216. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 289 | Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2021, 109, 12-16. | 1.5 | 11 |
| 290 | Adenylate cyclase blockers dissociate PTH-stimulated bone resorption from cAMP production. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1990, 258, E708-E714. | 1.8 | 10 |
| 291 | Adipokine Effects on Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 240-248. | 1.3 | 10 |
| 292 | Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. <i>American Journal of Medicine</i> , 2012, 125, e15. | 0.6 | 10 |
| 293 | Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. <i>Osteoporosis International</i> , 2017, 28, 1867-1874. | 1.3 | 10 |
| 294 | Osteoporosis: evidence for vitamin D and calcium in older people. <i>Drug and Therapeutics Bulletin</i> , 2020, 58, 122-125. | 0.3 | 10 |
| 295 | Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. <i>PLoS ONE</i> , 2015, 10, e0139975. | 1.1 | 10 |
| 296 | Zoledronate: Efficacy and Safety. <i>Journal of Bone and Mineral Research</i> , 2006, 21, P83-P87. | 3.1 | 9 |
| 297 | Response to publication of PRISM trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1463-1464. | 3.1 | 9 |
| 298 | Misclassification does not explain increased cardiovascular risks of calcium supplements. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 959-959. | 3.1 | 9 |
| 299 | Comment on Kanis et al.: Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2013, 24, 389-390. | 1.3 | 9 |
| 300 | The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 364-365. | 5.5 | 9 |
| 301 | Reasons for discrepancies in hip fracture risk estimates using FRAX and Garvan calculators. <i>Maturitas</i> , 2016, 85, 11-18. | 1.0 | 9 |
| 302 | Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone. <i>Calcified Tissue International</i> , 2017, 101, 43-49. | 1.5 | 9 |
| 303 | Osteoporosis –emerging consensus. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 643-647. | 0.5 | 8 |
| 304 | Calcium Supplements and Nail Quality. <i>New England Journal of Medicine</i> , 2000, 343, 1817-1817. | 13.9 | 8 |
| 305 | Re: The calcium scare: what would Austin Bradford Hill have thought?. <i>Osteoporosis International</i> , 2011, 22, 3079-3080. | 1.3 | 8 |
| 306 | Calcium supplements and cardiovascular risk. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 899-899. | 3.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Denosumab after 8 years. Osteoporosis International, 2015, 26, 2759-2761. | 1.3 | 8 |
| 308 | Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. Calcified Tissue International, 2017, 100, 250-254. | 1.5 | 8 |
| 309 | Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women. Osteoporosis International, 2017, 28, 119-125. | 1.3 | 8 |
| 310 | Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. Journal of Bone and Mineral Research, 2020, 36, 61-66. | 3.1 | 8 |
| 311 | Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Archives of Internal Medicine, 1995, 155, 1813-5. | 4.3 | 8 |
| 312 | Preventing glucocorticoid-induced osteoporosis. Zeitschrift Fur Rheumatologie, 2000, 59, 1197-11102. | 0.5 | 7 |
| 313 | Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. Osteoporosis International, 2009, 20, 141-150. | 1.3 | 7 |
| 314 | Calcium supplements and cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 497-498. | 6.1 | 7 |
| 315 | Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684. | 2.0 | 7 |
| 316 | Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. Osteoporosis International, 2017, 28, 733-734. | 1.3 | 7 |
| 317 | Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells. Calcified Tissue International, 2019, 105, 497-505. | 1.5 | 7 |
| 318 | Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. BoneKey Reports, 2016, 5, 852. | 2.7 | 7 |
| 319 | Calcium and cardiovascular risks. Australian Prescriber, 2013, 36, 5-8. | 0.5 | 7 |
| 320 | Revisiting osteoporosis guidelines. Lancet Diabetes and Endocrinology, the, 2021, 9, 805-806. | 5.5 | 7 |
| 321 | Steroid osteoporosis. Osteoporosis International, 1993, 3, 144-146. | 1.3 | 6 |
| 322 | Maintaining the Trust of Physicians and the Public in the Medical Literature: Report of a Task Force on Scientific Publishing of Clinical Trials. Journal of Bone and Mineral Research, 2007, 22, 1661-1667. | 3.1 | 6 |
| 323 | Vitamin D – let's get back to the evidence base. IBMS BoneKey, 2010, 7, 249-253. | 0.1 | 6 |
| 324 | Intervals Between Bone Density Testing. Journal of Bone and Mineral Research, 2014, 29, 389-391. | 3.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2016, 98, 474-478. | 1.5 | 6 |
| 326 | Fibroblast growth factor 23 levels decline following sleeve gastrectomy. <i>Clinical Endocrinology</i> , 2019, 91, 87-93. | 1.2 | 6 |
| 327 | Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification. <i>Bone Reports</i> , 2019, 10, 100190. | 0.2 | 6 |
| 328 | A prediction tool for vitamin D deficiency in New Zealand adults. <i>Archives of Osteoporosis</i> , 2020, 15, 172. | 1.0 | 6 |
| 329 | Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047. | 3.1 | 6 |
| 330 | Authors' response to editorial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3520-d3520. | 2.4 | 5 |
| 331 | Skeletal Actions of Fasting-Induced Adipose Factor (FIAF). <i>Endocrinology</i> , 2013, 154, 4685-4694. | 1.4 | 5 |
| 332 | Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016, 27, 2637-2639. | 1.3 | 5 |
| 333 | High-dose vitamin D: Without benefit but not without risk. <i>Journal of Internal Medicine</i> , 2018, 284, 694-696. | 2.7 | 5 |
| 334 | Denosumab for glucocorticoid-induced osteoporosis. <i>Nature Reviews Endocrinology</i> , 2018, 14, 383-384. | 4.3 | 5 |
| 335 | Calcium and Bone. <i>Handbook of Experimental Pharmacology</i> , 2019, 262, 259-280. | 0.9 | 5 |
| 336 | Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2020, 106, 386-391. | 1.5 | 5 |
| 337 | Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. <i>Arthritis and Rheumatology</i> , 2021, 73, 1758-1764. | 2.9 | 5 |
| 338 | Calcium and vitamin D: To supplement or not?. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 693-698. | 0.6 | 5 |
| 339 | Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009, 20, 835-836. | 1.3 | 4 |
| 340 | Bisphosphonate Therapy for Secondary Osteoporosis: Adult Perspective. <i>Hormone Research in Paediatrics</i> , 2011, 76, 28-32. | 0.8 | 4 |
| 341 | Calcium supplements and cardiovascular risk in the Women's Health Initiative. <i>Osteoporosis International</i> , 2013, 24, 2371-2372. | 1.3 | 4 |
| 342 | No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial. <i>Calcified Tissue International</i> , 2013, 92, 1-5. | 1.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Controversyâ€”cardiovascular effects of calcium supplementation. Nature Reviews Endocrinology, 2014, 10, 641-642. | 4.3 | 4 |
| 344 | Vitamin D supplements do not reduce mortality risk. BMJ, The, 2014, 348, g2860-g2860. | 3.0 | 4 |
| 345 | Vitamin D Supplements and the Risk of Falls. JAMA Internal Medicine, 2015, 175, 1723. | 2.6 | 4 |
| 346 | Controversies in osteoporosis management. Internal Medicine Journal, 2016, 46, 767-770. | 0.5 | 4 |
| 347 | Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. Calcified Tissue International, 2018, 102, 73-84. | 1.5 | 4 |
| 348 | Benefits, Risks and Costs of Calcium Supplementation in Postmenopausal Women. Pharmacoeconomics, 1994, 5, 1-4. | 1.7 | 3 |
| 349 | The investigation of hypercalcaemia. Clinical Endocrinology, 1994, 41, 405-406. | 1.2 | 3 |
| 350 | Emerging Issues With Bisphosphonates. Rheumatic Disease Clinics of North America, 2006, 32, 691-702. | 0.8 | 3 |
| 351 | Adipose Tissue and Bone. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 207-209. | 1.3 | 3 |
| 352 | Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253. | 3.8 | 3 |
| 353 | Long-chain triazolyl acids as inhibitors of osteoclastogenesis. Bioorganic and Medicinal Chemistry, 2013, 21, 4112-4119. | 1.4 | 3 |
| 354 | An inappropriate response?. BMJ, The, 2013, 346, f942-f942. | 3.0 | 3 |
| 355 | Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. Annals of Internal Medicine, 2014, 160, 655. | 2.0 | 3 |
| 356 | Treatment of Pagetâ€™s Disease of Bone. , 2016, , 119-136. | | 3 |
| 357 | Vitamin D supplements do not prevent falls. BMJ, The, 2016, 353, i3005. | 3.0 | 3 |
| 358 | Calcium fortified foods or supplements for older people?. Maturitas, 2016, 85, 1-4. | 1.0 | 3 |
| 359 | Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. Calcified Tissue International, 2019, 105, 423-429. | 1.5 | 3 |
| 360 | No more fracture trials in osteoporosis?. Lancet Diabetes and Endocrinology,the, 2020, 8, 650-651. | 5.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 996-997. | 3.1 | 3 |
| 362 | Bisphosphonate holidays. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 35-36. | 0.3 | 3 |
| 363 | Bone-friendly lifestyle and the role of calcium or vitamin D supplementation. <i>Climacteric</i> , 2022, 25, 37-42. | 1.1 | 3 |
| 364 | "Cherry picking" did not occur in studied example. <i>BMJ: British Medical Journal</i> , 2010, 341, c5009-c5009. | 2.4 | 3 |
| 365 | Longer femoral necks in the young: a predictor of further increases in hip fracture incidence?. <i>New Zealand Medical Journal</i> , 1996, 109, 234-5. | 0.5 | 3 |
| 366 | Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 94-101. | 0.5 | 3 |
| 367 | Osteoporosis: non-HRT treatments. <i>Reviews in Gynaecological Practice</i> , 2002, 2, 48-53. | 0.1 | 2 |
| 368 | Calcium supplementation for older men and women?. <i>Osteoporosis International</i> , 2009, 20, 2147-2148. | 1.3 | 2 |
| 369 | Is calcium supplementation a risk factor for cardiovascular diseases in older women?. <i>Nutrition Reviews</i> , 2009, 67, 424-424. | 2.6 | 2 |
| 370 | Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 514-515. | 0.2 | 2 |
| 371 | Great strides made but still further to go. <i>Nature Reviews Endocrinology</i> , 2015, 11, 633-634. | 4.3 | 2 |
| 372 | Pathogenesis of Osteoporosis. , 2019, , 222-232. | | 2 |
| 373 | Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People. <i>EClinicalMedicine</i> , 2019, 12, 8-9. | 3.2 | 2 |
| 374 | Osteomalacia in subtropical Auckland. <i>BMJ Case Reports</i> , 2019, 12, e229657. | 0.2 | 2 |
| 375 | The effect of age on the microarchitecture and profile of gene expression in femoral head and neck bone from patients with osteoarthritis. <i>Bone Reports</i> , 2020, 13, 100287. | 0.2 | 2 |
| 376 | Molecular characterisation of osteoblasts from bone obtained from people of Polynesian and European ancestry undergoing joint replacement surgery. <i>Scientific Reports</i> , 2021, 11, 2428. | 1.6 | 2 |
| 377 | Stopping osteoporosis medications. <i>Journal of Internal Medicine</i> , 2021, 290, 1102-1104. | 2.7 | 2 |
| 378 | Pathogenesis of osteonecrosis of the jaw. <i>IBMS BoneKEy</i> , 2008, 5, 69-77. | 0.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Recent advances in understanding and managing Paget's disease. F1000Research, 2019, 8, 1485. | 0.8 | 2 |
| 380 | Government funding of health research in New Zealand. New Zealand Medical Journal, 2014, 127, 25-30. | 0.5 | 2 |
| 381 | Vitamin D sufficiency: reply to letter by Heaney. Osteoporosis International, 2007, 18, 835-836. | 1.3 | 1 |
| 382 | The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Obstetrical and Gynecological Survey, 2009, 64, 462-463. | 0.2 | 1 |
| 383 | Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice, 2010, 64, 1719-1722. | 0.8 | 1 |
| 384 | Morbidity and mortality in mild primary hyperparathyroidism. Clinical Endocrinology, 2010, 73, 688-688. | 1.2 | 1 |
| 385 | Characterization of and Risk Factors for the Acute-Phase Response After Zoledronic Acid. Obstetrical and Gynecological Survey, 2011, 66, 97-99. | 0.2 | 1 |
| 386 | Validation of BioDent TDI as a New Clinical Diagnostic Method. Advanced Materials Research, 2011, 275, 151-154. | 0.3 | 1 |
| 387 | Reply to RT Chlebowski et al. American Journal of Clinical Nutrition, 2012, 95, 259. | 2.2 | 1 |
| 388 | What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. BMJ, The, 2013, 346, f3413-f3413. | 3.0 | 1 |
| 389 | Observational studies "just telling us what we want to hear or telling us where we need to look?. Journal of Bone and Mineral Research, 2013, 28, 980-983. | 3.1 | 1 |
| 390 | Calcium, phosphate and magnesium. , 2014, , 93-123. | | 1 |
| 391 | Benefits of Calcium Supplements Are Too Small for Clinical Equipoise to Exist. Journal of Bone and Mineral Research, 2014, 29, 1914-1915. | 3.1 | 1 |
| 392 | Vitamin D supplements and bone mineral density " Authors' reply. Lancet, The, 2014, 383, 1293-1294. | 6.3 | 1 |
| 393 | Vitamin D: Present and future. Revista Clinica Espanola, 2014, 214, 383-384. | 0.2 | 1 |
| 394 | Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. Osteoporosis International, 2015, 26, 173-178. | 1.3 | 1 |
| 395 | Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730. | 1.3 | 1 |
| 396 | Monitoring Osteoporosis Therapy. Journal of Bone and Mineral Research, 2020, 36, 1423-1424. | 3.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Cardiovascular Safety of Calcium Supplements. , 2013, , 365-372. | | 1 |
| 398 | Relationships Between Body Fat and Bone Mass. , 2013, , 83-92. | | 1 |
| 399 | Response to letter by Ralston et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L47-L48. | 1.8 | 1 |
| 400 | Response to Letter. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L38-L38. | 1.8 | 1 |
| 401 | The role of dietary calcium in the pathogenesis and treatment of osteoporosis. New Zealand Medical Journal, 1989, 102, 532-3. | 0.5 | 1 |
| 402 | How Often Should We Measure Bone Density?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4267-e4268. | 1.8 | 1 |
| 403 | Osteoporosis Research in Auckland. Clinical Science, 1995, 88, 12-14. | 1.8 | 0 |
| 404 | Effects of calcium supplementation on bone and other end-points in normal older women â€œ The Auckland Calcium Study. International Congress Series, 2007, 1297, 82-88. | 0.2 | 0 |
| 405 | Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis. , 2008, , 1659-1685. | | 0 |
| 406 | Once-yearly zoledronateâ€”an effective preventative therapy for new fractures after hip fracture?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 308-309. | 2.9 | 0 |
| 407 | Amylin and Calcitonin Gene-Related Peptide. , 2008, , 837-853. | | 0 |
| 408 | Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. Annals of Pharmacotherapy, 2012, 46, 1267-1268. | 0.9 | 0 |
| 409 | Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. Annals of Internal Medicine, 2012, 156, 904. | 2.0 | 0 |
| 410 | Calcium supplementsâ€”vascular risks versus bone benefits?. Nature Reviews Endocrinology, 2013, 9, 255-256. | 4.3 | 0 |
| 411 | New insights into ONJ. IBMS BoneKEy, 2013, 10, . | 0.1 | 0 |
| 412 | Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis. , 2013, , 1701-1737. | | 0 |
| 413 | Response to letter to editor. Osteoporosis International, 2014, 25, 2501-2501. | 1.3 | 0 |
| 414 | Vitamin D and falls â€œ Authors' reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 541. | 5.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Screening for Vitamin D Deficiency. <i>Annals of Internal Medicine</i> , 2015, 162, 736. | 2.0 | 0 |
| 416 | Calcium and vitamin D do not prevent fractures in community-dwelling adults. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 185-186. | 1.7 | 0 |
| 417 | Steroid-Induced Osteoporosis. , 2006, , 689-699. | | 0 |
| 418 | Clinical Aspects of the Use of Vitamin D and Its Metabolites in Osteoporosis. , 2010, , 319-331. | | 0 |
| 419 | Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601. | | 0 |
| 420 | Response to the letter by Asik M., et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L36-L36. | 1.8 | 0 |
| 421 | Establishing healthy bones in the young. <i>Australian Family Physician</i> , 1997, 26, 132-4. | 0.5 | 0 |
| 422 | A new receptor to turn on bone growth. <i>New Zealand Medical Journal</i> , 2002, 115, 169-70. | 0.5 | 0 |
| 423 | All people should wear sunscreen or other protection for their skin whenever they are exposed to sunlight: no. <i>Journal of Primary Health Care</i> , 2013, 5, 156-7. | 0.2 | 0 |